Introduction
GM-CSF is one of the most powerful cytokines for enhancing the efficacy of autologous vaccines in several tumour models including melanoma and prostate cancer. [1] [2] [3] However, subsequent attempts to translate these successes to the clinic have been hampered by the practical difficulty of raising enough autologous cells from each individual patient. 4 The use of allogeneic vaccines would not only overcome these problems, it also has immunological rationale in the body of data illustrating that tumour antigens from tumour vaccine cells are presented to naive T cells by the host's own antigen presenting cells. [5] [6] [7] [8] This phenomenon of 'cross-priming' eliminates the need for MHC matching in the case of allogeneic vaccine strategy. However, this approach demands that the allogeneic tumour cells used as vaccine share some cross-reactive antigens with the autologous tumour. Therefore, work showing that human melanoma tumour antigens are shared in at least 50% of patients [9] [10] [11] is highly significant to the allogeneic vaccine strategy in that it makes it feasible to prepare a single vaccine containing a set of representative antigens, thereby making this a highly practical approach to translate to the clinic if it can be shown to work in a therapeutic setting. 12 There are now several reports of allogeneic vaccine efficacy in animal models.
13- 18 Morton and colleagues 19 have transferred this strategy to the clinic using unmodified allogeneic cells. However, early reports of allogeneic vaccines modified to secrete IL-2 have reported a limited response. 20, 21 As pre-clinical models for autologous vaccines show GM-CSF to be more potent than IL-2, it would seem logical to expect that this may also extend to allogeneic vaccines. A recent report 22 showed that GM-CSF enhanced the protective ability of autologous tumour vaccine cells modified to express an allogeneic MHC. On this basis, Jaffee and colleagues 23 have initiated recruitment for a clinical trial using a GM-CSF-secreting allogeneic vaccine to treat pancreatic adenocarcinoma.
In this report, we have used a completely allogeneic GM-CSF secreting tumour cell vaccine for the treatment of a melanoma tumour. Using the B16-F10 (H-2b) melanoma model, we have shown that allogeneic vaccine K135-M2 8, 18 (H-2k) induced a response that was specific and dependent on both CD4+ve and CD8+ve T cells. We then genetically modified the allogeneic vaccine cells to secrete GM-CSF and show their anti-tumour efficacy against established tumour.
Results
Specificity of the allogeneic cell vaccine Allogeneic vaccine K1735-M2 (H-2k) is known to confer protection against the syngeneic B16-F10 (H-2b) tumour 8, 18 ( Figure 1a ), whereas the autologous vaccine B16-F10 is ineffective (P = 0.0021). The specificity of this unmodified vaccine was investigated in two ways: first, as this cellular vaccine was derived from C3H/HeN mice, C57BL/6J mice were vaccinated with C3H/HeN allogeneic fibroblasts that were not expected to express any tumour antigens. These fibroblasts were initially characterised by flow cytometry and shown to express low levels of MHC class I antigen comparable to those of the K1735-M2 vaccine (data not shown). Figure 1b shows that unlike the allogeneic vaccine K1735-M2, allogeneic fibroblasts conferred no protection against the B16-F10 tumour; indeed, there was a significant difference between the two vaccination groups (P = 0.0022).
The second investigation on vaccine specificity was to assess whether the response induced by the allogeneic vaccine only protected against B16-F10 or if it protected animals against other syngeneic tumours. Thus, the animals were vaccinated with the allogeneic vaccine and then challenged with the 3LL Lewis lung carcinoma, a tumour syngeneic to C57BL/6J mice. The 3LL cells were comparable to B16-F10 cells in terms of growth ( Figure  1c) . Protection experiments then demonstrated that whilst allogeneic vaccine K1735-M2 protected against B16-F10, it was ineffective against 3LL, Figure 1d (P = 0.0005).
Immunization with allogeneic cell vaccine induces B16-F10 specific CTLs In order to investigate whether the protective response induced by allogeneic vaccination was T cell-mediated, we carried out cytotoxic T cell assays. Splenocytes were prepared from animals 11 days after vaccination and stimulated in vitro for 5 days with irradiated IFN-␥ treated B16-F10 cells. The ability of these lymphocytes to lyse IFN-␥ treated B16-F10 target cells was then determined in a standard 4-h 51 Cr release assay. Figure 2a shows data illustrating that immunisation with allogeneic cell vaccine K1735-M2 generates cytotoxic T cells against B16-F10. Figure 2b then shows that the cytotoxic T cells generated by the allogeneic vaccine are relatively specific for the B16-F10 tumour as opposed to the 3LL carcinoma or C57BL/6 mouse fibroblasts.
Antitumour activity promoted by the allogeneic K1735-M2 vaccine is dependent on both CD4+ve and CD8+ve T cells Having demonstrated in vitro that vaccination with allogeneic cell vaccine K1735-M2 generates B16-F10 specific
Figure 2 Allogeneic K1735-M2 vaccine generates B16-F10 specific cytotoxic T cells. (a) A comparison of the percentage of specific lysis (y-axis) of IFN-␥ treated, 51 Cr-labelled B16-F10 target cells by lymphocytes from allogeneic (̅), autologous (í) and PBS () vaccinated animals. The xaxis corresponds to the effector:target ratio (E:T). (b) A comparison of the percentage of specific lysis (y-axis) of IFN-␥ treated 51 Cr-labelled target cells (B16-F10 melanoma, 3LL lung carcinoma and C57BL/6 mouse fibroblasts) by lymphocytes from allogeneic vaccinated animals (data representative of two experiments).
T cells, we set up experiments to determine the in vivo relevance of T cells in mediating the effects of the allogeneic cell vaccine. Thus, CD4+ve and CD8+ve T cells were depleted in animals before vaccination. Figure 3 shows that the effect of the vaccine was abrogated in the absence CD8+ve T cells (P = 0.001) and of CD4+ve T cells (P = 0.0029) compared with animals that received a control antibody.
GM-CSF secreting allogeneic vaccine is effective in treatment studies
The involvement of both CD4+ve and CD8+ve T cells in mediating the effects of the allogeneic vaccine led us to believe that it operated via the indirect pathway of antigen presentation also known as 'cross-priming' 5, 6 which involves the autologous APC. GM-CSF cytokine improves the recruitment and maturation of professional APCs 24 as well as the efficacy of autologous whole cell melanoma vaccines. [1] [2] [3] We therefore decided to assess the anti-tumour activity of GM-CSF-secreting allogeneic tumour cells. K1735-M2 vaccine cells were transduced with a GM-CSF expressing retroviral vector and a clone secreting 32.75 ng per 10 6 irradiated cells per 48 h. These GM-CSF secreting K1735-M2 vaccine cells were then used in treatment experiments where unmodified K1735-M2 vaccine cells had already proved ineffective (data not shown and see Figure 4a ). Figure 4a shows the antitumour activity of allogeneic vaccine infected to secrete GM-CSF. There was a significant difference between the survival of animals vaccinated with unmodified allogeneic and autologous vaccine and those which received the GM-CSF secreting allogeneic vaccine (P = 0.019). There was no difference between the animals which received PBS and those that were administered the unmodified allogeneic vaccine cells (P = 0.1938).
Comparison of allogeneic and autologous GM-CSF secreting vaccines in treatment studies
Having demonstrated efficacy of the GM-CSF secreting allogeneic cell vaccine in a treatment setting, we trans- 
Figure 4 Anti-tumour activity against B16-F10 of GM-CSF secreting allogeneic vaccine cells. (a) A survival curve of C57BL/6J mice inoculated on day 0 with syngeneic B16-F10 cells (5 × 10 3 cells) and vaccinated on day 3, 7, 10 and 14 with PBS (᭹), wild-type K1735-M2 allogeneic cell (᭺), wild-type B16-F10 autologous cells (í) or GM-CSF-secreting allogeneic K1735-M2 cells (). (b) A direct comparison of the efficacy of the allogeneic () and autologous (᭺) GM-CSF secreting vaccines in a therapeutic setting.
duced B16-F10 autologous tumour cells with the GM-CSF expressing retroviral vector in order to carry out a direct comparison between the allogeneic and autologous GM-CSF secreting cell vaccines. Several B16-F10 GM-CSF secreting clones were generated, one was selected (clone 6) on the basis that it exhibited a similar level of GM-CSF secretion to the K1735-M2/GM-CSF clone used in the previous treatment experiments, (31 ng per 10 6 irradiated cells per 48 h). These two GM-CSF secreting cell vaccines were then used in treatment experiments. Figure 4b shows that, at these levels of GM-CSF secretion, the autologous vaccine displayed no anti-tumour activity. This was in contrast to the allogeneic cell vaccine which generated antitumour activity (P = 0.004).
Discussion
We have shown that a completely allogeneic tumour cell vaccine, engineered to secrete GM-CSF, has anti-tumour activity against the B16-F10 tumour in a therapeutic setting. The success of allogeneic K1735-M2 vaccine cells is likely to be due to 'cross-priming' tumour antigen presentation whereby antigens on the tumour vaccine cells are released in the vicinity of the vaccination site and then processed and presented to naive T cells by autologous professional APC [5] [6] [7] 25 making any requirement for MHC matching between the vaccine tumour cells and the vaccine recipient unnecessary.
Although we do not know the possible cross-reactive antigen(s) being targeted by the immune response, the in vitro T cell work showed that the allogeneic vaccine generated B16-F10 specific CTLs. This was further validated by in vivo depletion experiments, which, conducted in preventative vaccination with unmodified allogeneic vaccine cells, implicated both CD4+ve and CD8+ve T cells as mediators of the anti-tumour response. In addition, experiments focusing on both the tumour vaccine cell type and the tumour cell challenge showed that the K1735-M2 allogeneic cell vaccine was tumour and melanoma (B16-F10) specific. K1735-M2 and B16-F10 melanoma cells share at least one antigen, the B700 26 antigen, and we are at present trying to identify other antigens shared by these two melanomas and to determine the cross-reactive antigen(s) target of the immune response promoted by the allogeneic vaccine. The present allogeneic model has significance for the human situation as all the human melanoma antigens identified so far are shared by at least 50% of patients. [9] [10] [11] Indeed, other tumours like renal carcinoma appear to follow the same pattern 27 and 35% of lung carcinomas express the melanoma-specific antigens MAGE. 28 As a certain degree of cross-reactive antigens are present in different human tumours, the allogeneic vaccination strategy has therefore relevance for human tumours other than melanoma. However, this approach cannot, in theory, utilise tumour antigens which are unique to each individual patient as they will not be shared between the patient tumour and the allogeneic vaccine cells.
Allogeneic tumour cells vaccines have been investigated in pre-clinical models by several groups 13-18 with the finding that vaccination with completely allogeneic vaccine cells can induce a protective response against a subsequent challenge with live autologous tumour cells. So far the only evidence of T cell involvement in the response induced by the allogeneic vaccination was by in vitro CTL data [14] [15] [16] with the exception of Ashley and colleagues 13 who also demonstrated, as in the present study, that an allogeneic cell line (a pre-B cell line, 300.19), modified to express a specific model antigen (human epidermal growth factor receptor variant (EGFRvIII)), mediated anti-tumour activity against intracranial established tumours also expressing the model antigen (B16-F10 melanoma and 560 astrocytoma) through both CD4+ve and CD8+ve T cells. To our knowledge, there is no report of efficacy of GM-CSF secreting allogeneic whole tumour cell vaccine in both prevention and treatment of established tumours. Thomas and colleagues 22 have however demonstrated enhancement of tumour efficacy with GM-CSF genetic modification of autologous tumour cells also genetically engineered to express allogeneic MHC. One report has demonstrated that autologous tumour cells mixed with allogeneic fibroblasts secreting IL-2 could prolong survival of animals with established B16 tumours. 29 Our data showed that GM-CSF secreting allogeneic melanoma cell vaccine can prolong the survival and achieve a complete response in 20% of animals bearing established B16-F10 tumours, albeit at an early stage of tumour development (ie 3 days after tumour cell challenge). The experimental protocol is comparable with the protocol reported by Dranoff and colleagues 1 on the investigation of GM-CSF autologous B16-F10 as a whole cell therapeutic vaccine. Although the level of anti-tumour activity recorded with the GM-CSF-secreting allogeneic vaccine was not as high as that reported by Dranoff and co-workers 1 for the autologous cell vaccine, we believe the discrepancy is due to the difference in levels of GM-CSF secretion attained. We have experienced difficulties in achieving levels of GM-CSF secretion as reported by Dranoff and colleagues 1 but our levels are similar to those attained by several other groups. [30] [31] [32] A possible explanation for the discrepancy in GM-CSF levels is that Dranoff and colleagues 1 used the MFG vector which lacks an internal promoter for the selectable marker gene, presence of this promoter could lead to interference with the promoter for the GM-CSF gene thus leading to lower levels of secretion.
When a direct comparison was made between the autologous and allogeneic vaccines secreting comparable levels of GM-CSF in a therapeutic setting, the autologous vaccine failed to show any anti-tumour activity. It is likely that this was due to the much lower levels of GM-CSF secreted by our vaccines in comparison to those reported by Dranoff and colleagues. 1 Indeed, Jaffee and co-workers 23 have recently demonstrated that the amount of GM-CSF secreted by cell vaccines is critical to the magnitude of the immune response generated -with the lower levels failing to induce strong anti-tumour immunity. Moreover, another group, working with autologous vaccines secreting similar levels of GM-CSF to our vaccine, have also found their vaccine ineffective in the therapeutic setting. 30 It is therefore possible that the modest level of anti-tumour activity generated by the GM-CSF secreting allogeneic vaccine is supported by the alloresponse that the allogeneic vaccine would induce.
Our initial studies were designed to investigate whether allogeneic vaccines could substitute for autologous vaccines. The finding that allogeneic vaccines can confer added protection in both murine and rat models 33 suggests that the allogeneic signal is breaking tolerance to tumour antigens by acting as a 'danger signal' and/or inducing a graft-versus-tumour response similar to the graft-versus-leukaemia effect which is well documented in leukaemia patients after allogeneic bone marrow grafting. 34, 35 At present there are several clinical studies using allogeneic vaccine cells genetically modified to secrete IL-2, 20, 21 and GM-CSF 23 for tumour immunotherapy. Usually the protocols of these studies have been designed in order that the allogeneic tumour vaccine cells share at least one HLA antigen with the vaccine recipient (for example HLA-A2). Unlike the autologous cell vaccine situation where human studies were preceded by preclinical evaluation of the cytokine secreting vaccine in several murine models, this has not been the case for the cytokine secreting allogeneic tumour cell vaccine. The animal model that we have described in this report could help the evaluation of GM-CSF secreting allogeneic tumour cell vaccines and it could also be used to investigate cytokine combinations more potent than GM-CSF for allogeneic whole cell vaccines.
Materials and methods
Animals C57BL/6J and C3H/HeN female mice were obtained from B&K (Hull, UK) and used when approximately 12-15 weeks old. A general anaesthesia was used for all procedures which were carried out in accordance with the Animals Scientific Procedures Act 1986.
Tumour cell lines
The B16-F10 36 and K1735-M2 37 melanoma cell lines were a kind gift from Dr D Bennet (St George's Hospital Medical School, London, UK) and Professor IJ Fidler (MD Anderson, Houston, TX, USA). The 3LL 38 Lewis lung carcinoma was obtained from the European Cell Culture Collection. They were grown in Eagle's MEM with 2 mm l-glutamine, 1 × MEM non-essential amino acids, 1 mm sodium pyruvate, 50 U/ml penicillin, 50 g/ml streptomycin and 5% heat inactivated foetal calf serum. The B16-F10 cell line was grown at 37°C in 10% CO 2 whereas K1735-M2 and 3LL cell lines were incubated in 5% CO 2 . B16-F10 and K1735-M2 cells were passaged with 0.05% trypsin and 0.02% EDTA, whilst the 3LL cells were simply scraped off the plastic. All cell lines were routinely tested for the presence of mycoplasma using the GenProbe detection kit (Gene Probe, San Diego, CA, USA) and found free of mycoplasma contamination.
Preparation of allogeneic and autologous fibroblasts
Under sterile conditions, kidney tissue was removed from C3H/HeN and C57BL/6 mice. The tissues were dissected into small sections (1 × 1 × 1 mm), washed in Hanks balanced salt buffer (HBSS) and incubated (1 h, 37°C) in HBSS containing 0.5 mg/ml collagenase (Sigma, Poole, UK). The samples were then washed twice and the pellet resuspended in Dulbecco's MEM with 20% FCS, 2 mm l-glutamine, 50 U/ml penicillin and 50 g/ml streptomycin. The cells, with typical fibroblast morphology were cultured at 37°C in 5% CO 2 and passaged with 0.05% trypsin.
Tumourigenicity studies B16-F10 and 3LL cells were harvested, washed three times in PBS and administered to C57BL/6J mice by a subcutaneous flank injection (5 × 10 5 cells per mouse). The animals were examined three times a week for signs of a tumour. All animals were killed when the tumours reached a diameter of 15 mm.
Vaccination protocol for prevention experiments C3H/HeN fibroblasts, allogeneic (K1735-M2) and autologous (B16-F10) vaccine cells were harvested with 0.02% EDTA (without trypsin) and washed three times in sterile PBS to remove any serum proteins and irradiated at 100 Gy. The animals were then vaccinated (1 × 10 7 cells per 0.2 ml PBS) on the right flank. Eleven days later, the animals were challenged with 5 × 10 5 cells (B16-F10 or 3LL) on the opposite flank. The animals were monitored for palpable tumour and were killed when tumour diameter reached 15 mm.
Generation of cytotoxic T cells
Cytotoxic T lymphocyte assays were carried out as previously outlined by Dranoff and colleagues. 1 In brief, animals were vaccinated with either allogeneic or autologous cell vaccines, 11 days later, splenocytes were prepared using ammonium chloride to remove erythrocytes. The resulting lymphocyte preparation was washed and stimulated in vitro with irradiated IFN-␥ treated B16-F10 cells at an effector:stimulator ratio of 50:1. 39 of the IgG2b isotype were purified from tissue culture supernatant on a protein G Sepharose affinity column (Pharmacia Biotech). Bound antibody was eluted with 0.1 m glycine (pH 2.56) and dialysed against PBS before use. C57BL/6J mice were each injected i.p. with 0.25 mg of antibody (per day) in 0.5 ml PBS for 3 consecutive days. A rat IgG (Sigma, Poole, UK) was used as control antibody. On day 6, the depletion of CD4 and CD8 T cells in both the spleen and inguinal lymph nodes was verified by flow cytometry using FITC conjugated anti-CD4 and CD8 antibodies (Sigma). The animals were given twice weekly injections of antibody (0.25 mg per mouse) to maintain the depletion.
Transfection of K1735-M2 and B16-F10 cell lines with the GM-CSF gene A GM-CSF retroviral vector was made by splicing a fragment from the murine GM-CSF cDNA vector pXM (Genetics Institute) into the plasmid pBabeneo 40 which already had the neomycin resistance gene. PA317 packaging cells were transfected with the resulting plasmid by calcium phosphate precipitation and then selected in G418 containing medium. They were then ring cloned to select the higher GM-CSF producing clone (called PGA15). Supernatant containing GM-CSF encoding retroviruses from PGA15 cells was then used to infect K1735-M2 and B16-F10 cells in the presence of 8 g/ml of polybrene (Sigma). Transduced K1735-M2 and B16-F10 cells were selected in media containing G418 (0.4 mg/ml and 3.0 mg/ml, respectively) and single clones were picked by ring cloning. The level of GM-CSF secreted by transduced K1735-M2 and B16-F10 cells was determined by ELISA to be 32.75 and 30 ng/10 6 irradiated cells per 48 h, respectively (R&D Systems, UK). Secretion of GM-CSF by both cell lines was found to be stable for at least 10 passages.
Vaccination protocol for treatment experiments B16-F10 cells were harvested with 0.02% EDTA in trypsin, washed three times in PBS and inoculated in C57BL/6J mice (5 × 10 3 cells per mouse) on day 0. The animals were then vaccinated with irradiated K1735-M2, B16-F10, B16-F10/GM-CSF or K1735-M2/GM-CSF tumour cells (1 × 10 7 cells per mouse) on days 3, 7, 10 and 14. Thereafter, the animals were checked for palpable tumour and terminated when the diameter reached 15 mm.
Statistical analysis
Survival curves were compared using the log-rank test (two-tailed P value) on the GraphPad Prism statistical package, (San Diego, CA, USA). A P value of less than 0.05 was considered significant.
